Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor
A potent SARS coronavirus (CoV) 3CL protease inhibitor (TG- 0205221, K-i = 53 nM) has been developed. TG- 0205221 showed remarkable activity against SARS CoV and human coronavirus ( HCoV) 229E replications by reducing the viral titer by 4.7 log (at 5 mu M) for SARS CoV and 5.2 log (at 1.25 mu M) for...
Gespeichert in:
| Veröffentlicht in: | Journal of medicinal chemistry Jg. 49; H. 16; S. 4971 - 4980 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
WASHINGTON
Amer Chemical Soc
10.08.2006
|
| Schlagworte: | |
| ISSN: | 0022-2623, 1520-4804 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | A potent SARS coronavirus (CoV) 3CL protease inhibitor (TG- 0205221, K-i = 53 nM) has been developed. TG- 0205221 showed remarkable activity against SARS CoV and human coronavirus ( HCoV) 229E replications by reducing the viral titer by 4.7 log (at 5 mu M) for SARS CoV and 5.2 log (at 1.25 mu M) for HCoV 229E. The crystal structure of TG- 0205221 (resolution = 1.93 angstrom) has revealed a unique binding mode comprising a covalent bond, hydrogen bonds, and numerous hydrophobic interactions. Structural comparisons between TG- 0205221 and a natural peptide substrate were also discussed. This information may be applied toward the design of other 3CL protease inhibitors. |
|---|---|
| Bibliographie: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 0022-2623 1520-4804 |
| DOI: | 10.1021/jm0603926 |